RIVASTIGMINE TARTRATE
RIVASTIGMINE TARTRATE is indicated for the treatment of Mild-to-moderate dementia of the Alzheimer’s type; Mild-to-moderate dementia associated with Parkinson’s disease.
How RIVASTIGMINE TARTRATE Works
Rivastigmine tartrate is thought to exert its therapeutic effect by enhancing cholinergic function. It achieves this by increasing the concentration of acetylcholine through the reversible inhibition of its hydrolysis by the enzyme cholinesterase. Because the drug works by maintaining available acetylcholine, its clinical effect may diminish as the disease advances and fewer cholinergic neurons remain functionally intact.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2007-10-22
- Routes
- ORAL
- Dosage Forms
- CAPSULE
Companies
RIVASTIGMINE TARTRATE Approval History
What RIVASTIGMINE TARTRATE Treats
2 indicationsRIVASTIGMINE TARTRATE is approved for 2 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Mild-to-moderate dementia of the Alzheimer’s type
- Mild-to-moderate dementia associated with Parkinson’s disease
RIVASTIGMINE TARTRATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
RIVASTIGMINE TARTRATE FDA Label Details
Indications & Usage
RIVASTIGMINE TARTRATE is indicated for the treatment of Mild-to-moderate dementia of the Alzheimer’s type; Mild-to-moderate dementia associated with Parkinson’s disease.
Looking for the branded version?
EXELON
Full clinical data, patents, trials, and competitive landscape for rivastigmine tartrate.
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment